# Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma

> **NCT04589832** · PHASE1,PHASE2 · TERMINATED · sponsor: **Arkadiusz Z. Dudek, MD** · enrollment: 6 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** PAC-1
- **DRUG:** Entrectinib

## Key facts

- **NCT ID:** NCT04589832
- **Lead sponsor:** Arkadiusz Z. Dudek, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-11
- **Primary completion:** 2022-03-22
- **Final completion:** 2022-06-24
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** This study required dose reductions to the lower dose level (Dose level -1). But this dose level (Dose level -1) was not further explored because of lack of funding.
- **Last updated:** 2023-11-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04589832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04589832, "Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04589832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*